Literature DB >> 15901933

DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy.

Nino Keshelava1, Tomás Frgala, Jirí Krejsa, Ondrej Kalous, C Patrick Reynolds.   

Abstract

DIMSCAN is a semiautomatic fluorescence-based digital image microscopy system that quantifies relative total (using a DNA stain) or viable (using fluorescein diacetate [FDA]) cell numbers in tissue culture multiwell plates ranging from 6 to 384 wells per plate. DIMSCAN is a rapid and efficient tool for conducting in vitro cytotoxicity assays across a 4 log dynamic range. The specificity of detecting viable cells with FDA is achieved by using digital image processing and chemical quenching of fluorescence in nonviable cells with eosin Y. Average scan time for the most commonly used format, a 96-well plate, is 6 min. Cytotoxicity for neuroblastoma cell lines measured by DIMSCAN was found to be comparable to manual Trypan blue dye exclusion counts or colony formation in soft agar, but with a significantly wider dynamic range, which enables drug combination studies used to detect synergistic or antagonistic interactions. The linearity of DIMSCAN was validated (r2 = 0.99967 +/- 0.0003) for cells stained with FDA deposited using a fluorescence-activated cell sorter, documenting a dynamic range > 4 logs, and the ability to detect a single viable cell in a well 93% of the time. DIMSCAN has been used to demonstrate preclinical activity of cytotostatic and cytotoxic drugs and drug combinations that have subsequently shown activity in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15901933     DOI: 10.1385/1-59259-869-2:139

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  25 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.

Authors:  Hua Fang; Theresa M Harned; Ondrej Kalous; Vanessa Maldonado; Yves A DeClerck; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

3.  Novel cell lines established from pediatric brain tumors.

Authors:  Jingying Xu; Anat Erdreich-Epstein; Ignacio Gonzalez-Gomez; Elizabeth Y Melendez; Goar Smbatyan; Rex A Moats; Michael Rosol; Jaclyn A Biegel; C Patrick Reynolds
Journal:  J Neurooncol       Date:  2011-11-27       Impact factor: 4.130

4.  Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Authors:  Richard Gorlick; E Anders Kolb; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2012-02-07       Impact factor: 3.167

5.  Initial testing of lenalidomide by the pediatric preclinical testing program.

Authors:  C Patrick Reynolds; Min H Kang; Stephen T Keir; Richard Gorlick; E Anders Kolb; Richard Lock; John M Maris; Hernan Carol; Christopher L Morton; Catherine A Billups; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

6.  The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.

Authors:  Mei-Chuan Chen; Bingsen Zhou; Keqiang Zhang; Yate-Ching Yuan; Frank Un; Shuya Hu; Chih-Ming Chou; Chun-Han Chen; Jun Wu; Yan Wang; Xiyong Liu; D Lynne Smith; Hongzhi Li; Zheng Liu; Charles D Warden; Leila Su; Linda H Malkas; Young Min Chung; Mickey C-T Hu; Yun Yen
Journal:  Mol Pharmacol       Date:  2015-03-26       Impact factor: 4.436

7.  Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

Authors:  W Cai; N V Maldonado; W Cui; N Harutyunyan; L Ji; R Sposto; C P Reynolds; N Keshelava
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

8.  Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.

Authors:  Stephen T Keir; John M Maris; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Christopher L Morton; Jianrong Wu; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-01-17       Impact factor: 3.167

9.  Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.

Authors:  C Patrick Reynolds; Min H Kang; Hernan Carol; Richard Lock; Richard Gorlick; E Anders Kolb; Raushan T Kurmasheva; Stephen T Keir; John M Maris; Catherine A Billups; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2012-09-21       Impact factor: 3.167

10.  Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines.

Authors:  Gabriela González-Agüero; Andrés A Gutiérrez; Diana González-Espinosa; José D Solano; Rocío Morales; Aliesha González-Arenas; Edith Cabrera-Muñoz; Ignacio Camacho-Arroyo
Journal:  Endocrine       Date:  2007-11-15       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.